Novartis AIN457 Study
Study Title
An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis
Enrollment Status
Patients are being enrolled in the uveitis clinical trial called the Novartis AIN457 study, that are designed to investigate the safety and effectiveness of an investigational biological medication for people with active or inactive non-infectious intermediate, posterior, or pan-uveitis.
Purpose
Patients enrolled in this study will have the following outcomes measured:
- Safety assessments will include ocular examinations, physical examination, and adverse events
- Reduction in ocular inflammation
- Reduction in other immunosuppressant drugs
- Ability to induce a remission in uveitis
- Duration of remission in uveitis
- Ability to re-induce a remission if a flare-up occurs
Eligibility
Dr. C. Micheal Samson, Uveitis Specialist and Principal Investigator of this study can determine if you are eligible.
Inclusion Criteria
- Men and Women of 18 Years to 75 years of age
- Active uveitis (i.e., uveitis that is not in remission).
- Intermediate uveitis, posterior uveitis, or panuveitis must be sufficiently severe that systemic immunosuppression is indicated.
Exclusion criteria:
- Active infection.
- Other protocol-defined inclusion/exclusion criteria may apply
This is a fully funded trial. All research related procedures and medication will be at no cost to the patient.
Contact Information
To see if you qualify and to make an appointment for the Novartis AIN457 study, please call Katy Tai, Clinical Research Manager at 212-979-4251.
Home > Current Research > Clinical Trials in Ophthalmology > Novartis AIN457 stUDY
